Healthcare / Drug Manufacturers - GeneralUpdated 2026-05-10 22:07 UTC

ETR/ZEG stock hub

ETR/ZEG has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

ETR/ZEGis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

239.6B

Deutsche Börse Xetra

Market data

Live price

Current market quote for this ticker.

Current price

ETR/ZEG

In the news

Latest news · ETR/ZEG

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E17.1

P25 12.3P50 15.7P75 20.2

Trailing P/E26.6

P25 16.4P50 20.9P75 30.4

ROE23.5

P25 -6.7P50 8.5P75 17.2

ROIC16.4

P25 -1.7P50 8.5P75 17.4

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All ETR/ZEG market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

242

Groups with data

Currency

USD

Showing 242 of 242 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	United Kingdom
Country code	DE
Employees	96,100
Employees Change	4,400%
Employees Change Percent	4.89
Enterprise value	EUR 262.7B
Exchange	Deutsche Börse Xetra
Financial currency	USD
First seen	2026-05-10
Industry	Drug Manufacturers - General
Isin	GB0009895292
Last refreshed	2026-05-10
Market cap	EUR 239.6B
Price	EUR 161
Price currency	EUR
Rev Per Employee	545,460.4x
Sector	Healthcare
Sic	2834
Symbol	etr/ZEG
Website	https://www.astrazeneca.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	3.76%
EV Earnings	29.16x
EV/EBIT	20.1x
EV/EBITDA	14.7x
EV/FCF	26.83x
EV/Sales	4.96x
FCF yield	4.09%
Forward P/E	17.11x
P/B ratio	5.83x
P/E ratio	26.59x
P/S ratio	4.57x
PE Ratio10 Y	84.81x
PE Ratio3 Y	31.68x
PE Ratio5 Y	131.57x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	24.69%
EBITDA Margin	33.08%
FCF margin	18.68%
Gross margin	81.51%
Gross Profit	EUR 42.7B
Gross Profit Growth	8.69%
Gross Profit Growth Q	11.17%
Gross Profit Growth3 Y	10.18%
Gross Profit Growth5 Y	17.61%
Net Income	EUR 9B
Net Income Growth	33.67%
Net Income Growth Q	5.62%
Net Income Growth Quarters	10%
Net Income Growth Years	4%
Net Income Growth3 Y	30.22%
Net Income Growth5 Y	21.17%
Pretax Margin	21.37%
Profit Margin	17.19%
Profit Per Employee	EUR 93,760
Profitable Years	36
ROA	8.47
Roa5y	5.95
ROCE	18.32
ROE	23.48
Roe5y	13.03
ROIC	16.4
Roic5y	13.29

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	15.05%
Cagr15y	13.86%
Cagr1y	24.5%
Cagr20y	10.24%
Cagr3y	13.65%
Cagr5y	16.69%
Div CAGR10	0.86%
Div CAGR3	0.36%
Div CAGR5	2.78%
EPS Growth	33.61
EPS Growth Q	5.35
EPS Growth Quarters	10
EPS Growth Years	4
EPS Growth3 Y	30.03
EPS Growth5 Y	16.98
FCF Growth	1.26%
FCF Growth Q	-14.37%
FCF Growth3 Y	9.55%
FCF Growth5 Y	15.06%
OCF Growth	8.66%
OCF Growth Q	-9.53%
OCF Growth10 Y	11.98%
OCF Growth3 Y	13.57%
OCF Growth5 Y	16.62%
Revenue Growth	9.93x
Revenue Growth Q	12.51x
Revenue Growth Quarters	12x
Revenue Growth Years	7x
Revenue Growth3 Y	11.3x
Revenue Growth5 Y	16.99x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	EUR 0.55
Assets	EUR 98.9B
Cash	EUR 6.7B
Current Assets	EUR 25.1B
Current Liabilities	EUR 27.6B
Debt	EUR 29.5B
Debt EBITDA	EUR 1.67
Debt Equity	EUR 0.72
Debt FCF	EUR 3.01
Equity	EUR 41.1B
Interest Coverage	10.59
Liabilities	EUR 57.8B
Long Term Assets	EUR 73.8B
Long Term Liabilities	EUR 30.2B
Net Cash	EUR -22.9B
Net Cash By Market Cap	EUR -9.54
Net Debt EBITDA	EUR 1.32
Net Debt Equity	EUR 0.56
Net Debt FCF	EUR 2.33
Tangible Book Value	EUR -9.3B
Tangible Book Value Per Share	EUR -6.03
WACC	5.24

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	0.91
Inventory Turnover	1.8
Net Working Capital	EUR -2.2B
Quick ratio	0.7
Working Capital	EUR -2.6B
Working Capital Turnover	EUR -17.63

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	0.08%
Dividend Growth	-7.66%
Dividend Growth Years	4%
Dividend per share	EUR 2.71
Dividend Years	26
Dividend Yield	1.69%
Ex Div Date	2026-02-19
Last Dividend	EUR 1.83
Payout Frequency	Semi-Annual
Payout Ratio	46.07%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	306.21%
1Y total return	24.48%
200-day SMA	138.6
3Y total return	46.82%
50-day SMA	158.1
50-day SMA vs 200-day SMA	50over200
5Y total return	116.37%
All Time High	166.3
All Time High Change	-3.37%
All Time High Date	2026-01-15
All Time Low	22.38
All Time Low Change	618.05%
All Time Low Date	2008-03-18
ATR	3.36
Beta	0.22
Ch YTD	1.81
High	161.2
High52	166.3
High52 Date	2026-01-15
High52ch	-3.37%
Low	157.9
Low52	111
Low52 Date	2025-04-09
Low52ch	44.78%
Ma50ch	1.62%
Price vs 200-day SMA	15.96%
RSI	53.92
RSI Monthly	62.68
RSI Weekly	63.27
Sharpe ratio	0.52x
Sortino ratio	1
Total Return	1.77%
Tr YTD	2.98
Tr15y	600.36%
Tr1m	3.97%
Tr1w	4.47%
Tr3m	14.35%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	EUR 12.9B
Operating Income Growth	10.65
Operating Income Growth Q	17.2
Operating Income Growth3 Y	14.17
Operating Income Growth5 Y	29.99
Operating margin	24.69

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	1,543,451,508%
Net Borrowing	1,010,770,704
Shares Insiders	0.04%
Shares Institutions	68.53%
Shares Qo Q	-0.13%
Shares Yo Y	-0.08%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	EUR 9.5B
Average Volume	10,875.65x
Bv Per Share	26.5
CAPEX	EUR -2.5B
Ch10y	195.5
Ch15y	346.4
Ch1m	2.78
Ch1w	3.28
Ch1y	20.47
Ch20y	308.4
Ch3m	13.05
Ch3y	36.19
Ch5y	90.76
Ch6m	25.55
Change	0.59%
Change From Open	1.13
Close	159.8
Days Gap	-0.53
Depreciation Amortization	4,299,167,340
Dollar Volume	2,285,314.7
Earnings Date	2026-04-29
EBIT	EUR 12.9B
EBITDA	EUR 17.3B
EPS	EUR 5.76
F Score	7
FCF	EUR 9.8B
FCF EV Yield	3.73x
Financing CF	-3,963,561,000
Fiscal Year End	December
Founded	1,992
Goodwill	17,971,706,628
Graham Number	61.22025
Graham Upside	-61.9
Income Tax	EUR 2.2B
Investing CF	-6,372,053,100
Is Primary Listing	0
Last Earnings Date	2026-04-29
Last Report Date	2026-03-31
Lynch Fair Value	EUR 128
Lynch Upside	-20.38
Ma150	143.4
Ma150ch	12.04%
Ma20	159.6
Ma20ch	0.72%
Net CF	2,000,861,100
Next Earnings Date	2026-07-27
Open	158.9
P FCF Ratio	24.46
P OCF Ratio	19.43
Payment Date	2026-03-23
Position In Range	84.85
Ppne	12,669,400,242
Price Date	2026-02-05
Price EBITDA	EUR 13.82
Relative Volume	1.31x
Revenue	52,418,744,700x
SBC By Revenue	0.61x
Share Based Comp	317,431,800
Tax By Revenue	4.17x
Tax Rate	19.52%
Tr20y	602.93%
Tr6m	27.88%
Volume	14,221
Z Score	3.35

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

ETR/ZEG dividend yield, growth & safety

Yield, payout sustainability, and the multi-year growth streak.

Dividend yield

+1.7%

$2.71 annual per share

Payout ratio

+46.1%

Share of earnings returned as dividends. Below 60% is generally sustainable.

5Y dividend CAGR

+2.8%

4 consecutive years of growth

Total shareholder yield

+1.8%

Next ex-dividend date: 2026-02-19

Performance

ETR/ZEG stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns ETR/ZEG?

Insider, institutional, and short-interest positioning.

Institutional ownership

+68.5%

Share of float held by funds and institutions

Insider ownership

+0.0%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

-0.1%

Negative means the company is buying back shares.

Technical

ETR/ZEG momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

53.9

Neutral momentum band

Price vs 200-day MA

+16.0%

50/200-day relationship not available

Beta (5Y)

0.22

Less volatile than the market

Sharpe ratio

0.52

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About ETR/ZEG

Hub-level FAQ points readers to the deeper analysis pages.

What is the current etr/ZEG stock rating?

etr/ZEG is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full etr/ZEG analysis?

The full report lives at /stocks/etr/ZEG/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for etr/ZEG?

The latest report frames etr/ZEG around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the etr/ZEG page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.